Surgery Partners Management
Management Kriterienprüfungen 4/4
Surgery Partners CEO ist J. Evans , ernannt in Jan 2020, hat eine Amtszeit von 6.58 Jahren. Die jährliche Gesamtvergütung beträgt $6.08M , bestehend aus 17.3% Gehalt und 82.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.71% der Aktien des Unternehmens, im Wert von $13.82M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.5 Jahre bzw. 7.6 Jahre.
Wichtige Informationen
J. Evans
Geschäftsführender
US$6.1m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 17.26% |
| Amtszeit als Geschäftsführer | 6.6yrs |
| Eigentum des Geschäftsführers | 0.7% |
| Durchschnittliche Amtszeit des Managements | 4.5yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 7.6yrs |
Jüngste Management Updates
Recent updates
Narrative-Update • Jun 30
SGRY: Q1 Execution And 2026 Outlook Will Support Margin Recovery
Analysts have revised their fair value estimate for Surgery Partners from $25.00 to about $23.49, citing updated assessments of discount rates, revenue growth, profit margins, and future P/E assumptions based on recent research. Analyst Commentary Recent Street research around Surgery Partners highlights a mix of adjustments to price targets, with some bullish analysts focusing on the company’s capacity to execute on its plans while reassessing risk and return assumptions.Analyseartikel • Jun 19
Surgery Partners (SGRY) Stock Could Be 19% Undervalued As Growth And Debt Concerns Build
Recent commentary on Surgery Partners (SGRY) has focused on slowing sales volume growth, softer revenue growth expectations, and ongoing high debt levels. This combination appears to be affecting sentiment toward the stock. See our latest analysis for Surgery Partners. At a share price of $14.55, Surgery Partners has seen a 30 day share price return of 7.86% and a 90 day share price return of 23.31%. However, the 1 year total shareholder return is down 24.61%, pointing to some recent momentum...
Narrative-Update • Jun 15
SGRY: Reset Expectations And Steady Guidance Will Shape Future Multiple Potential
Analysts cut the fair value estimate for Surgery Partners stock by $4 to $14, reflecting updated assumptions around revenue growth, profit margins, the discount rate, and a lower future P/E multiple, despite recent mixed price target moves at Jefferies. Analyst Commentary Recent research shows mixed views on Surgery Partners, with some analysts adjusting price targets in both directions over a short period.
Narrative-Update • Jun 01
SGRY: Margin Repair And Payer Mix Reset Will Support 2026 EBITDA Recovery
The analyst-derived fair value estimate for Surgery Partners has shifted from about $18.80 to roughly $17.95, as analysts factor in recent price target cuts tied to Q4 margin pressures, a softer 2026 EBITDA outlook, and concerns around payer mix, anesthesia costs, and a slower M&A contribution. Analyst Commentary Recent Street research around Surgery Partners has been active, with multiple firms revisiting their models after Q4 results and updated 2026 guidance.Narrative-Update • May 02
SGRY: Margin Pressures Will Ease As 2026 M&A Upside Reemerges
Narrative Update on Surgery Partners Analysts have trimmed the average price target for Surgery Partners by a few dollars into the mid to high teens, citing Q4 EBITDA and margin shortfalls, a weaker payer mix, anesthesia related cost pressures, softer 2026 guidance, and reduced expectations for M&A contribution. Analyst Commentary Price targets across the Street have been revised lower into a tighter band, generally in the mid to low US$20s and mid to high teens, following the Q4 miss and 2026 EBITDA guidance that came in below prior expectations.Narrative-Update • Apr 18
SGRY: Margin Pressures Will Ease As M&A Optionality Reshapes 2026 Outlook
Analysts have reduced the average price target for Surgery Partners by roughly $8 to $10 per share to a range of about $14 to $24, citing Q4 EBITDA shortfalls, margin pressures from payer and insurance mix shifts, anesthesia related costs, and softer 2026 guidance that excludes potential M&A. Analyst Commentary Recent research shows that while price targets have moved lower across the Street, several bullish analysts still see upside potential for Surgery Partners relative to current trading levels.Narrative-Update • Apr 04
SGRY: Margin Repair And Payer Mix Management Will Support A Constructive 2026 Reset
The analyst price target for Surgery Partners has been reduced from about $25.45 to about $18.80. Analysts cite weaker Q4 EBITDA, margin pressure from a tougher payer and insurance mix, anesthesia-related cost pressures, and more cautious 2026 guidance as key drivers of their updated views.Narrative-Update • Mar 21
SGRY: Margin Reset And M&A Optionality Will Counter Anesthesia And Payer Mix Pressures
Narrative Update on Surgery Partners The analyst price target for Surgery Partners has moved lower by several dollars into a $14 to $24 range, as analysts factor in recent Q4 EBITDA shortfalls, weaker margins, anesthesia and payer mix headwinds, and management's 2026 guidance that sits below prior consensus and assumes limited M&A. Analyst Commentary Recent Street commentary on Surgery Partners centers on Q4 earnings that came in below expectations, margin pressure tied to anesthesia costs, and a less favorable payer mix.Narrative-Update • Mar 06
SGRY: Margin Reset And M&A Optionality Are Expected To Ease Payer Mix Pressures
The analyst fair value estimate for Surgery Partners has been reduced from $33.00 to $25.00 as analysts factor in lower Q4 EBITDA, margin pressure related to payer mix and anesthesia costs, and softer 2026 guidance that assumes fewer deals than previously modeled. Analyst Commentary Street research has broadly reset expectations on Surgery Partners, with several firms lowering their price targets after Q4 results and the updated 2026 outlook.Narrative-Update • Feb 20
SGRY: New Baylor Partnership Will Set Up Future Multiple Rebound Potential
Analysts have kept their $18.00 price target for Surgery Partners unchanged, citing consistent assumptions regarding revenue growth, profit margins, and future P/E as support for this view. What's in the News Surgery Partners agreed to a new partnership with Baylor Scott & White Health to jointly own The Physicians Centre Hospital, a 16 bed facility in Bryan, Texas, alongside physicians (Key Developments).Narrative-Update • Feb 06
SGRY: Payer Mix Pressures Will Set Up Future Multiple Rebound Potential
Analysts have reduced their price target on Surgery Partners to US$18 from US$24, citing weaker earnings visibility from payer mix and volume pressures, a higher discount rate, more conservative revenue growth assumptions, and an adjustment to a lower future P/E multiple. Analyst Commentary Recent research updates on Surgery Partners point to a reset in expectations, with several firms cutting price targets across the board.Narrative-Update • Jan 23
SGRY: Asset Divestitures And Deleveraging Are Expected To Reset Payer Mix Pressures
Narrative Update Analysts have reduced their price targets on Surgery Partners to a range of roughly US$18 to US$31, citing lower earnings visibility tied to payer mix and volume pressures, slower M&A activity, and updated guidance that still assumes a favorable backdrop for asset divestitures and ambulatory surgery center demand. Analyst Commentary Across recent research updates, analysts have generally reduced price targets for Surgery Partners into the US$18 to US$31 range while still highlighting several areas that they see as supportive for the equity story.Narrative-Update • Jan 09
SGRY: Upcoming Divestitures And Deleveraging Will Support A Constructive 2025 Reset
Analysts have trimmed their price targets on Surgery Partners, resulting in a modest change in estimated fair value from about $25.73 to $25.45, as they factor in payer mix pressure, softer recent performance, slower M&A activity, and updated expectations for volumes and earnings visibility. Analyst Commentary Recent research paints a mixed picture for Surgery Partners, with price targets moving lower but opinions split on how temporary the current pressures might be.Narrative-Update • Dec 25
SGRY: Upcoming Asset Divestitures Are Expected To Drive Material Balance Sheet Deleveraging
Analysts have trimmed their fair value estimate for Surgery Partners to $33 from $36. This reflects lower price targets across the Street as they factor in softer volume trends, payer mix headwinds, reduced earnings visibility and a slower M&A cadence, partially offset by confidence in long term ASC tailwinds and de-leveraging from asset divestitures.Narrative-Update • Dec 11
SGRY: Upcoming Divestitures And Deleveraging Will Drive A Constructive Reset In 2025
Surgery Partners price target has been revised lower, with analysts trimming expectations by mid single digit dollars per share to reflect weaker than expected recent performance, payer mix and volume pressures, slower M&A activity, and reduced near term earnings visibility, even as they highlight supportive long term fundamentals and a still constructive outlook on asset divestitures and deleveraging. Analyst Commentary Analysts are broadly revising models to reflect weaker near term trends, yet most still frame the stock as a valuation reset rather than a change in the long term thesis.Narrative-Update • Nov 27
SGRY: Upcoming Divestitures And Deleveraging Will Drive Recovery In 2025
Analysts have lowered their price target for Surgery Partners from approximately $27.91 to $25.73. They cite recent earnings misses, payer mix headwinds, and delayed acquisitions as primary factors for the revision.Narrative-Update • Nov 12
SGRY: Asset Divestitures And Acquisition Pipeline Will Drive Recovery Ahead
The analyst price target for Surgery Partners has decreased from $31 to approximately $27.91. Analysts cite lowered guidance due to slowing volume and payer mix trends, a delay in acquisitions, and a more cautious outlook for near-term growth.Seeking Alpha • Sep 08
Surgery Partners: Deleveraging Needs To Be The Priority
Summary Surgery Partners now trades at fair value after multiple compression, with returns on capital still lagging and leverage elevated, justifying my Hold rating. Q2 results were decent, but cash flow conversion and ambitious H2 margin targets highlight execution risks and limited room for error. Business economics show SGRY is capital intensive, with ROIC below the cost of capital, so growth currently destroys value unless returns improve. To upgrade my stance, I need to see sustained high-teen margins, clear deleveraging, and a shift to higher organic growth over acquisitions. Read the full article on Seeking AlphaNeues Narrative • May 26
Ambulatory Surgery Trends And Aging Will Expand Market Reach
Growth is driven by rising surgical case volumes in lower-cost centers and expanded specialties, supported by demographic trends and strategic network expansion.Seeking Alpha • Jan 30
Surgery Partners: A Buyout Could Be Justifiable Around This Level
Summary Surgery Partners received a non-binding offer from Bain Capital to acquire the rest of the company for $25.75 per share, valuing it at $3.25 billion. In the past, the stock had been pricey, but this is no longer the case based on current pricing. In recent years, financial performance has been solid and improving, particularly when it comes to cash flows. The market is cautiously optimistic about the offer, suggesting potential for a higher bid, but significant upside is unlikely. Read the full article on Seeking AlphaAnalyseartikel • Dec 08
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues Pushing Shares 28% Lower
The Surgery Partners, Inc. ( NASDAQ:SGRY ) share price has fared very poorly over the last month, falling by a...Analyseartikel • Nov 11
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Oct 24
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues
It's not a stretch to say that Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.4x right...Analyseartikel • Oct 05
Surgery Partners (NASDAQ:SGRY) Has Some Way To Go To Become A Multi-Bagger
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...Analyseartikel • Jul 25
Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward
Surgery Partners, Inc. ( NASDAQ:SGRY ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • Jul 13
Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analyseartikel • Jun 21
Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Analyseartikel • May 31
We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now
Key Insights Surgery Partners will host its Annual General Meeting on 6th of June CEO J. Evans' total compensation...Analyseartikel • Apr 24
Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion
There wouldn't be many who think Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.2x is...Analyseartikel • Mar 18
Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analyseartikel • Feb 27
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Dec 19
The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)
There wouldn't be many who think Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.5x is...Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$89m |
| Mar 31 2026 | n/a | n/a | -US$76m |
| Dec 31 2025 | US$6m | US$1m | -US$78m |
| Sep 30 2025 | n/a | n/a | -US$171m |
| Jun 30 2025 | n/a | n/a | -US$180m |
| Mar 31 2025 | n/a | n/a | -US$193m |
| Dec 31 2024 | US$6m | US$1m | -US$168m |
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$34m |
| Mar 31 2024 | n/a | n/a | US$600k |
| Dec 31 2023 | US$6m | US$1m | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$54m |
| Mar 31 2023 | n/a | n/a | -US$92m |
| Dec 31 2022 | US$6m | US$1m | -US$55m |
| Sep 30 2022 | n/a | n/a | -US$31m |
| Jun 30 2022 | n/a | n/a | -US$29m |
| Mar 31 2022 | n/a | n/a | -US$38m |
| Dec 31 2021 | US$4m | US$1m | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$86m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$150m |
| Dec 31 2020 | US$4m | US$916k | -US$156m |
| Sep 30 2020 | n/a | n/a | -US$179m |
| Jun 30 2020 | n/a | n/a | -US$132m |
| Mar 31 2020 | n/a | n/a | -US$119m |
| Dec 31 2019 | US$5m | US$435k | -US$110m |
Vergütung im Vergleich zum Markt: J.Die Gesamtvergütung ($USD6.08M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD5.16M).
Entschädigung vs. Einkommen: J.Die Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
J. Evans (49 yo)
6.6yrs
Amtszeit
US$6,083,862
Vergütung
Mr. J. Eric Evans has been the Chief Executive Officer and Director of Surgery Partners, Inc. since January 13, 2020 and served as its Executive Vice President and Chief Operating Officer since April 1, 20...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$6.08m | 0.71% $ 13.8m | |
| Executive VP & CFO | 4.5yrs | US$2.68m | 0.17% $ 3.3m | |
| Executive VP and Chief Administrative & Development Officer | 6.5yrs | US$2.18m | 0.25% $ 4.9m | |
| Executive VP & Chief Strategy Officer | 4.6yrs | US$1.12m | 0.073% $ 1.4m | |
| Division President South | no data | US$1.27m | 0.081% $ 1.6m | |
| Executive VP & COO | less than a year | keine Daten | 0.093% $ 1.8m | |
| Senior VP & Chief Information Officer | 1.3yrs | keine Daten | keine Daten | |
| Senior VP & Chief Compliance Officer | 7.8yrs | keine Daten | keine Daten | |
| General Counsel & Senior VP | 2.4yrs | keine Daten | keine Daten | |
| Executive VP & Chief Human Resources Officer | 3.5yrs | keine Daten | 0.059% $ 1.2m | |
| Senior Vice President of Managed Care | 6.8yrs | keine Daten | keine Daten | |
| Senior VP & Enterprise Chief Clinical Officer | 2.7yrs | keine Daten | keine Daten |
4.5yrs
Durchschnittliche Betriebszugehörigkeit
46yo
Durchschnittliches Alter
Erfahrenes Management: SGRYDas Führungsteam des Unternehmens gilt als erfahren (4.5 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$6.08m | 0.71% $ 13.8m | |
| Independent Director | 8.8yrs | US$260.00k | 0.053% $ 1.0m | |
| Independent Chairman of the Board | 5.3yrs | US$345.00k | 0.041% $ 794.2k | |
| Independent Director | less than a year | keine Daten | 0.0090% $ 175.3k | |
| Independent Director | 10.7yrs | US$465.00k | 0.067% $ 1.3m | |
| Independent Director | 9.9yrs | US$430.00k | 0.044% $ 853.6k | |
| Independent Director | 7.3yrs | US$410.00k | 0.035% $ 689.5k | |
| Independent Director | 9yrs | keine Daten | keine Daten | |
| Independent Director | 1.6yrs | US$410.00k | 0.014% $ 278.2k | |
| Independent Director | 8yrs | keine Daten | keine Daten |
7.6yrs
Durchschnittliche Betriebszugehörigkeit
60.5yo
Durchschnittliches Alter
Erfahrener Vorstand: SGRYDie Vorstandsmitglieder gelten als erfahren (7.6 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/12 05:08 |
| Aktienkurs zum Tagesende | 2026/08/12 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Surgery Partners, Inc. wird von 21 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Steven Valiquette | Barclays |
| Sarah James | Barclays |
| Andrew Mok | Barclays |